Cargando…
Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk
Germline mutations in the human checkpoint gene, hCHK2, were first identified in 1999 in cases of Li–Fraumeni syndrome. Recent studies have demonstrated that the hCHK2 1100delC mutation acts as a low-penetrance tumour suppressor gene in familial breast cancer not associated with mutations in BRCA1 o...
Autores principales: | Varley, Jenny, Haber, Daniel A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC164998/ https://www.ncbi.nlm.nih.gov/pubmed/12793891 |
Ejemplares similares
-
CHEK2
(∗)1100delC Mutation and Risk of Prostate Cancer
por: Hale, Victoria, et al.
Publicado: (2014) -
CHEK2 1100 delC mutation in Russian ovarian cancer patients
por: Krylova, Nadezhda Yu, et al.
Publicado: (2007) -
Genomic profiling of CHEK2*1100delC-mutated breast carcinomas
por: Massink, Maarten P. G., et al.
Publicado: (2015) -
CHEK2 1100delC is prevalent in Swedish early onset familial breast cancer
por: Margolin, Sara, et al.
Publicado: (2007) -
A Case of Male Breast Cancer Patient with CHEK2*1100delC Mutation
por: Nguyen, Quan D, et al.
Publicado: (2020)